2026.7-至今 中国科学院上海有机化学研究所，任研究员
2022.8-2026.7 百济神州上海研发中心，参与建立百济神州研究院并担任实验室主任
2016.10-2022.8 哈佛大学医学院/Dana-Farber癌症研究所，先后担任博士后、讲师 (导师: Myles Brown)
2011.9-2016.9 荷兰莱顿大学，博士 （导师: Peter ten Dijke）
尽管新型肿瘤治疗药物不断涌现，患者对治疗原发性无应答和获得性耐药仍然普遍存在，许多疾病相关靶点缺乏精准、特异性的干预策略。其关键瓶颈在于我们对药物作用的分子机制及治疗诱导的生物学变化仍缺乏系统认识。
我们从临床治疗和药物发现的基本问题出发，以创新药物和化学分子为研究工具，系统解析肿瘤药物治疗响应的分子机制，发现调控信号通路和细胞命运等关键生物学过程的功能化合物，并推动其向创新治疗手段的转化。主要研究方向包括：（1）肿瘤靶向治疗药物的作用与耐药机制；（2）高通量筛选驱动的治疗靶点与药物发现；（3）基于生物学原理的创新治疗策略开发。
国家人才计划
上海市人才计划
浦东新区“明珠计划”菁英人才
美国癌症研究协会 (AACR) JUNE L. BIEDLER青年学者奖
Dana-Farber癌症研究所“Spotlight” 博士后
美国圣安东尼奥乳腺癌大会(SABCS) 青年学者奖
1. Li, Y*., Qiu, X., Sandusky, Z., Tagliaferri, K., Li, R., Yang, X., Zhang, T., Liu, S., Yan, P., and Lu, F. (2025). METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation. Proceedings of the National Academy of Sciences 122, e2514643122.
2. Li, Y., Qiu, X., Wang, X., Liu, H., Geck, R.C., Tewari, A.K., Xiao, T., Font-Tello, A., Lim, K., and Jones, K.L. (2021). FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nature Cell Biology 23, 1187-1198.
3. Li, Y., Cui, C., Xie, F., Kiełbasa, S., Mei, H., van Dinther, M., van Dam, H., Bauer, A., Zhang, L., and Ten Dijke, P. (2020). VprBP mitigates TGF-β and Activin signaling by promoting Smurf1-mediated type I receptor degradation. Journal of molecular cell biology 12, 138-151.
4. Li, Y., Jin, K., van Pelt, G.W., van Dam, H., Yu, X., Mesker, W.E., ten Dijke, P., Zhou, F., and Zhang, L. (2016). c-Myb enhances breast cancer invasion and metastasis through the Wnt/β-catenin/Axin2 pathway. Cancer research 76, 3364-3375.
5. Li, Y., Drabsch, Y., Pujuguet, P., Ren, J., van Laar, T., Zhang, L., van Dam, H., Clément-Lacroix, P., and Ten Dijke, P. (2015). Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Research 17, 1-16.
6. Li, Y., Kang, X., and Wang, Q. (2011). HSP70 decreases receptor-dependent phosphorylation of Smad2 and blocks TGF-β-induced epithelial-mesenchymal transition. Journal of Genetics and Genomics 38, 111-116.
7. Zhong, C., Jiang, W.-J., Yao, Y., Li, Z., Li, Y., Wang, S., Wang, X., Zhu, W., Wu, S., and Wang, J. (2024). CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer. Nature communications 15, 5502.
8. Wang, X., Tokheim, C., Gu, S.S., Wang, B., Tang, Q., Li, Y., Traugh, N., Zeng, Z., Zhang, Y., and Li, Z. (2021). In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell 184, 5357-5374. e5322.
9. Qiu, X., Feit, A.S., Feiglin, A., Xie, Y., Kesten, N., Taing, L., Perkins, J., Gu, S., Li, Y., and Cejas, P. (2021). CoBRA: containerized bioinformatics workflow for reproducible ChIP/ATAC-seq analysis. Genomics, Proteomics and Bioinformatics 19, 652-661.
10. Xie, F., Jin, K., Shao, L., Fan, Y., Tu, Y., Li, Y., Yang, B., van Dam, H., Ten Dijke, P., and Weng, H. (2017). FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. Nature communications 8, 15021.
11. Zhou, F., Drabsch, Y., Dekker, T.J., De Vinuesa, A.G., Li, Y., Hawinkels, L.J., Sheppard, K.-A., Goumans, M.-J., Luwor, R.B., and De Vries, C.J. (2014). Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling. Nature communications 5, 3388.
12. Zhang, L., Zhou, F., de Vinuesa, A.G., de Kruijf, E.M., Mesker, W.E., Hui, L., Drabsch, Y., Li, Y., Bauer, A., and Rousseau, A. (2013). TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Molecular cell 51, 559-572.
13. Zhang, L., Zhou, F., Li, Y., Drabsch, Y., Zhang, J., van Dam, H., and ten Dijke, P. (2012). Fas-associated factor 1 is a scaffold protein that promotes β-transducin repeat-containing protein (β-TrCP)-mediated β-catenin ubiquitination and degradation. Journal of Biological Chemistry 287, 30701-30710.
